CN106309506B - Probiotics composition with menstruation regulating function and application thereof - Google Patents
Probiotics composition with menstruation regulating function and application thereof Download PDFInfo
- Publication number
- CN106309506B CN106309506B CN201610846342.4A CN201610846342A CN106309506B CN 106309506 B CN106309506 B CN 106309506B CN 201610846342 A CN201610846342 A CN 201610846342A CN 106309506 B CN106309506 B CN 106309506B
- Authority
- CN
- China
- Prior art keywords
- cfu
- content
- bifidobacterium longum
- probiotic composition
- lactobacillus plantarum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 71
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 71
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000005906 menstruation Effects 0.000 title claims abstract description 49
- 230000000529 probiotic effect Effects 0.000 claims abstract description 45
- 206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 33
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 31
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 31
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 31
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 31
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 31
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 30
- 208000005171 Dysmenorrhea Diseases 0.000 claims abstract description 19
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 12
- 240000001008 Dimocarpus longan Species 0.000 claims description 10
- 235000000235 Euphoria longan Nutrition 0.000 claims description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 10
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 10
- 235000008397 ginger Nutrition 0.000 claims description 10
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 10
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 9
- 244000182216 Mimusops elengi Species 0.000 claims description 9
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 9
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 244000273928 Zingiber officinale Species 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000003821 menstrual periods Effects 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 38
- 230000006870 function Effects 0.000 description 33
- 239000000843 powder Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 241000234314 Zingiber Species 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 239000003223 protective agent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of biological medicines, and particularly relates to a probiotic composition with a menstruation regulating function and application thereof, which are suitable for dysmenorrhea in menstrual periods of women, particularly suitable for primary dysmenorrhea of young women. A probiotic composition with menstruation regulating effect comprises Lactobacillus rhamnosus, Lactobacillus plantarum and Bifidobacterium longum. The probiotic composition can also be compounded with medicinal and edible traditional Chinese medicines with menstruation regulating function, and has synergistic effect. The probiotics is an internationally recognized probiotic substance and has the advantages of safe source, obvious effect, no toxic or side effect and the like. The probiotic composition disclosed by the invention not only can be safely eaten, but also has a menstruation regulating function, particularly can be used for inhibiting primary dysmenorrhea, and provides a new application of probiotics. The probiotics and the medicine-food homologous traditional Chinese medicine are compounded to exert the advantages together, thereby achieving the effect of safely and effectively treating the dysmenorrhea.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to a probiotic composition with a menstruation regulating function and application thereof, which are suitable for dysmenorrhea in menstrual periods of women, particularly suitable for primary dysmenorrhea of young women.
Background
Dysmenorrhea is a common clinical gynecological disease, and refers to the symptoms of lower abdomen or waist pain, even lumbosacral pain during and before menstrual period; each time it occurs with the menstrual cycle, severe cases may be accompanied by nausea, vomiting, cold sweat, cold hands and feet, and even syncope. According to related investigation, the incidence rate of dysmenorrhea is 33.19%, the mild degree is 45.73%, the moderate degree is 38.81%, and the severe degree is 13.55%. The primary dysmenorrhea of young women reaches 75%, which brings serious influence to the life, social contact and health of women, and long-term dysmenorrhea can also cause infertility, induce various gynecological diseases, and simultaneously affect the development of infants in uterus.
At present, western medicines such as analgesics, hormone medicines and traditional Chinese medicines are commonly used in the market for treating dysmenorrhea, and the traditional Chinese medicines can be classified into two types: one is an oral conditioning type Chinese patent medicine product, such as rhizoma corydalis pain relieving capsule, ease pill, decoction of four ingredients, ai Fu warming uterus pill, etc., and the other is an external conditioning and health care type product, such as dysmenorrhea patch, motherwort warming uterus patch, etc. Chinese traditional medicine for treating dysmenorrhea such as CN200610002243.4 and CN 103585403A, CN 103656463A are prepared from common Chinese herbal medicines with effects of benefiting qi and nourishing blood, promoting blood circulation for removing blood stasis, warming channels for dispelling cold and relieving pain. The long-term taking of the medicine can cause psychological stress of patients and also can cause side effects of the medicine. It is therefore desirable to provide an edible product suitable for dysmenorrhea in women.
Probiotics is a kind of active microorganisms beneficial to a host, and is a general term for active beneficial microorganisms which are planted in the intestinal tract and the reproductive system of a human body and can generate definite health efficacy so as to improve the micro-ecological balance of the host and play beneficial roles. It is an internationally recognized safe food additive, has been widely applied to dairy products, health products and pharmaceutical industries, and is mainly used for regulating intestinal functions, reducing blood cholesterol level, preventing harmful substances from generating, delaying human body aging, regulating human body immunity, inhibiting lactose intolerance, resisting tumors and the like, such as Chinese patents CN101772308A, CN102511707A, CN101864375A, CN103653170A and the like. However, no report about the effect of probiotics on treating dysmenorrhea is available at present.
Disclosure of Invention
The inventor of the application finds that the probiotic composition consisting of lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum can be safely eaten, and has the function of regulating menstruation, and particularly can inhibit primary dysmenorrhea. The present invention has been completed based on this finding.
In view of the above, the present invention provides a probiotic composition with menstruation regulating effect, which is composed of edible probiotics and has the characteristics of safety and effectiveness. In addition, the probiotic composition can play a good role in inhibiting primary dysmenorrhea.
In order to achieve the purpose, the technical scheme of the invention is as follows:
a probiotic composition with menstruation regulating function comprises Lactobacillus rhamnosus, Lactobacillus plantarum and Bifidobacterium longum.
The intestinal flora is a possible factor causing metabolic diseases of an organism, and the probiotics are active microorganisms which are supplemented and ingested by the organism, can effectively improve the balance of the intestinal flora and produce good health effect on a host. A large number of researches show that the probiotic strains have physiological functions of regulating the balance of flora in vivo, improving the immunity of organisms, reducing serum cholesterol, blood pressure, blood sugar, resisting cancers and the like.
The tests prove that the probiotic composition also has the function of regulating menstruation.
Furthermore, in the probiotic composition, the content of lactobacillus rhamnosus is 2.5 × 106-2.5×109CFU/g, the content of the lactobacillus plantarum is 2.5 multiplied by 106-2.5×109CFU/g, the number of the bifidobacterium longum is 5 multiplied by 106-5×109CFU/g。
Further, the probiotic composition preferably contains lactobacillus rhamnosus and lactobacillus plantarum in an amount of 2.5 × 107CFU/g, the content of Bifidobacterium longum is 5 × 107CFU/g。
Furthermore, the probiotic composition has a ratio of viable count of lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum of 1: 1: 2.
the probiotic composition with the menstruation regulating function can be prepared according to the following method:
1) respectively activating Lactobacillus rhamnosus, Lactobacillus plantarum and Bifidobacterium longum with culture medium, inoculating into fermentation culture medium, and culturingThe body concentration reaches 0.5-2 multiplied by 10 of logarithmic growth phase9CFU/mL；
2) Centrifuging fermentation liquor of each strain in the step 1), discarding supernatant, and collecting bacterial sludge;
3) preparing a strain protective agent;
4) respectively and uniformly mixing the strain protective agent and each strain mud, then pre-freezing the mixture, and freeze-drying to prepare active probiotic powder;
5) taking each active probiotic powder, mixing according to the ratio of viable count of lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum, and uniformly mixing to obtain the probiotic composition with the function of regulating menstruation.
The strain protective agent can be a strain protective agent commonly used in the field.
In one specific embodiment, the formula of the bacterial powder protective agent is as follows: 8g of cane sugar, 26g of skim milk powder, 1mL of glycerol, 100mL of distilled water, 115 ℃ and 15min of sterilization.
Preferably, the obtained active probiotic bacteria powder is sieved and then mixed.
Preferably, the mixture is sieved by a sieve with 80-100 meshes.
The probiotic composition with the menstruation regulating function is composed of edible probiotics and has the characteristics of safety and effectiveness. In addition, experimental research proves that the probiotic composition has the function of regulating menstruation, and particularly has a good effect of inhibiting primary dysmenorrhea.
Therefore, the invention also protects the application of the probiotic composition in preparing products for treating dysmenorrheal and regulating menstruation besides protecting the probiotic composition. The product includes but is not limited to medicine, food and health care product.
The probiotic composition with the function of regulating menstruation can be added with one or more food and pharmaceutically acceptable carriers to be prepared into dosage forms such as tablets, powder, capsules and the like.
The invention also aims to provide a composition with the function of regulating menstruation, which is prepared by synergistically combining medicinal and edible traditional Chinese medicines with the function of regulating menstruation and probiotics with the function of regulating menstruation, overcomes the defects of long medication time and medicament side effect of single traditional Chinese medicine, and has synergistic effect by combining the two.
In order to achieve the purpose, the technical scheme of the invention is as follows:
the composition with the function of regulating menstruation is formed by synergistically combining probiotics and medicinal and edible traditional Chinese medicines with the function of regulating menstruation; the probiotics comprise lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum.
Further, the composition with the function of regulating menstruation comprises the probiotics, wherein the content of lactobacillus rhamnosus is 2.5 x 106-2.5×109CFU/g, the content of the lactobacillus plantarum is 2.5 multiplied by 106-2.5×109CFU/g, the number of the bifidobacterium longum is 5 multiplied by 106-5×109CFU/g。
Further, in the probiotics, preferably, the content of the lactobacillus rhamnosus and the lactobacillus plantarum is 2.5 multiplied by 107CFU/g, the content of Bifidobacterium longum is 5 × 107CFU/g。
Furthermore, in the probiotics, the ratio of the number of viable bacteria of the lactobacillus rhamnosus, the lactobacillus plantarum and the bifidobacterium longum is 1: 1: 2.
furthermore, the composition with the function of regulating menstruation is prepared from the medicinal and edible traditional Chinese medicines including honey-fried licorice root, medlar, red dates, dried orange peel, dried ginger and longan.
Preferably, the composition with the function of regulating menstruation comprises the following components in parts by weight: 5-10 parts of honey-fried licorice root, 6-12 parts of medlar, 6-20 parts of red date, 3-10 parts of dried orange peel, 3-10 parts of dried ginger and 9-15 parts of longan.
More preferably, the medicine-food homologous traditional Chinese medicine comprises the following components in parts by weight: 8 parts of honey-fried licorice root, 6 parts of medlar, 20 parts of red date, 10 parts of dried orange peel, 3 parts of dried ginger and 10 parts of longan.
The medicine and food homologous traditional Chinese medicine and the probiotics act synergistically and promote each other. The invention not only protects the composition with the function of regulating menstruation, but also protects the application of the composition in preparing products for treating dysmenorrheal and regulating menstruation. The product includes but is not limited to medicine, food and health care product.
Similarly, the composition with menstruation regulating function can also be added with one or more food and pharmaceutically acceptable carriers to prepare tablets, powder, capsules and other dosage forms.
The invention has the beneficial effects that:
(1) the probiotic composition with the menstruation regulating function, which is prepared by taking probiotics as raw materials, develops new application of the probiotics, has better effect on treating dysmenorrhea than traditional Chinese medicine products sold on the market, has the characteristics of safety and effectiveness, can promote proliferation of the probiotics in a human body, regulates intestinal flora of the human body while treating dysmenorrhea, and is beneficial to human health.
(2) The composition with the function of regulating menstruation is prepared by synergistically combining probiotics and medicinal and edible traditional Chinese medicines with the function of regulating menstruation, the traditional Chinese medicines and the probiotics are reasonably compatible for use, and experiments prove that the medicine effect is superior to that of any raw material used alone, the defects of long time and drug side effect of the traditional Chinese medicines used alone are overcome, and the synergistic effect is achieved by combining the probiotics and the traditional Chinese medicines.
Detailed Description
The examples are provided for better illustration of the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for modifying or modifying other embodiments for carrying out the same purposes of the present invention without departing from the scope of the invention as defined by the appended claims.
Application of first part of probiotic composition with menstruation regulating function
Example 1 probiotic composition having menstruation regulating function
A probiotic composition with menstruation regulating function comprises Lactobacillus rhamnosus, Lactobacillus plantarum and Bifidobacterium longum.
Probiotic composition formula 1: the ratio of viable count of lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum is 1: 1: 2, wherein the content of the lactobacillus rhamnosus and the lactobacillus plantarum is 2.5106CFU/g, content of Bifidobacterium longum is 5 × 106CFU/g。
Probiotic composition formula 2: the ratio of viable count of lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum is 1: 1: 2, wherein the content of lactobacillus rhamnosus and lactobacillus plantarum is 2.5 multiplied by 107CFU/g, content of Bifidobacterium longum is 5 × 107CFU/g。
Probiotic composition formula 3: the ratio of viable count of lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum is 1: 1: 2, wherein the content of lactobacillus rhamnosus and lactobacillus plantarum is 2.5 multiplied by 108CFU/g, content of Bifidobacterium longum is 5 × 108CFU/g。
Probiotic composition formula 4: the ratio of viable count of lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum is 1: 1: 2, wherein the content of lactobacillus rhamnosus and lactobacillus plantarum is 2.5 multiplied by 109CFU/g, content of Bifidobacterium longum is 5 × 109CFU/g。
Example 2 product having menstruation regulating function
The preparation method comprises the following steps:
(1) preparing active probiotic dry powder:
1) respectively activating Lactobacillus rhamnosus, Lactobacillus plantarum and Bifidobacterium longum with culture medium, inoculating into fermentation culture medium, shake culturing to make thallus concentration reach logarithmic growth phase of 0.5-2 × 109CFU/mL。
Preparation of bifidobacterium seed liquid: taking out the strain storage tube, scratching a plate with a bifidobacterium solid culture medium for resuscitation, and carrying out anaerobic culture at 37 ℃ for 48-72 hours. A single colony was picked up under the plate and inoculated into 50 ml of a culture medium for Bifidobacterium, and cultured in an anaerobic incubator for 48 hours. Inoculating 5% of the seed into a 3L large triangular flask (the liquid loading amount is 2.5L), sealing with sterile vegetable oil, performing anaerobic culture at 37 deg.C for 36-48 hr, and detecting the bacterial liquid concentration, wherein the bacterial content is 5 hundred million/ml, and the liquid fermentation can be terminated. Wherein the culture medium of bifidobacterium is as follows: casein peptone 1%, soybean peptone 0.5%, ferment0.25% of mother powder, 1.5% of glucose and K2HPO4 0.2％，MgCl2·6H2O 0.05％，CaCl2 0.015％，ZnSO4·7H2O 0.025％，FeCl30.01 percent, 0.005 percent of L-cysteine hydrochloride and 1mL of tween-801 (1000mL plus 1mL), adjusting the pH value to 6.5, adding 1.5 percent agar powder into a solid culture medium, and sterilizing for 15min under 0.1 MPa.
Preparation of lactobacillus seed liquid: taking out the strain preservation tube, scratching a flat plate by using an MRS solid culture medium for resuscitation, and carrying out anaerobic culture at 37 ℃ for 48 hours. Individual colonies were picked under the plate and inoculated into 100ml of MRS medium and anaerobically cultured in an incubator at 37 ℃ for 24 hours. Inoculating 5% of the seed into a 3L large triangular flask (the liquid loading amount is 2.5L), carrying out anaerobic culture at 37 ℃ for 24-48 hours, detecting the concentration of the bacterial liquid, and stopping the fermentation of the lactobacillus liquid when the bacterial content exceeds 10 hundred million/ml. Wherein, the MRS culture medium: 2.0% of glucose, 0.2% of ammonium citrate, 0.5% of sodium acetate, 0.5% of dipotassium phosphate, 0.02% of manganese sulfate, 0.05% of magnesium sulfate, 1.0% of peptone, 1.0% of beef extract, 0.5% of yeast extract, 800.1% of tween-E and 6.0% of PH; adding 1.5% agar powder into solid culture medium, and sterilizing at 0.1MPa for 15 min.
2) And mixing the fermentation liquids of all strains, centrifuging, discarding the supernatant, washing the thallus precipitate, centrifuging, and discarding the supernatant to obtain the bacterial sludge.
3) Preparing a bacterial powder protective agent, wherein the formula comprises 8g of sucrose, 26g of skimmed milk powder, 1mL of glycerol, 100mL of distilled water and 115 ℃, and sterilizing for 15 min.
4) And (3) fully mixing the bacterial powder protective agent and the bacterial mud, pre-freezing the mixture, and then carrying out vacuum freeze drying to obtain the active probiotic dry powder.
(2) Sieving
And (2) sieving the active probiotic dry powder obtained in the step (1) by a sieve of 80-100 meshes.
(3) Counting bacterial powder: and measuring the viable count of the probiotic dry powder by using a flat plate colony counting method.
(4) Preparing materials: weighing the screened probiotic dry powder, and mixing according to the viable count proportion of the lactobacillus rhamnosus, the lactobacillus plantarum and the bifidobacterium longum in the formula 1-4; the auxiliary material is skimmed milk powder.
(5) Mixing: and (3) fully and uniformly mixing the prepared probiotic compositions and auxiliary materials until the colors are uniform and consistent and no color difference exists, and obtaining products 1, 2, 3 and 4 with the function of regulating menstruation.
Example 3 test verification of product with menstruation regulating function
1. Animal experiments
Construction, grouping and administration of a mouse primary dysmenorrhea model: 80 female Kunming white mice of 18-22g are selected and randomly divided into 8 treatment groups, namely a blank control group, a model group, a positive group (commercially available Yueyueshutongjingbao granules), a product 1, a product 2, a product 3 and a product 4, wherein each group comprises 10 mice. Except the blank group, the other groups jointly replicate the primary dysmenorrheal model by estrogen and oxytocin, and the specific operation is as follows: at a dose of 10 mg/kg-1·d-1The uterus of the mice is synchronized by injecting estradiol benzoate into the abdominal cavity continuously for 10 days, equivalent distilled water is fed into a normal group and a model group from the 4 th day, equivalent drugs (the human body dosage is 20g/d, the daily administration dosage of the mice is converted according to the body surface area; the administration volume is 0.5 mL/mouse) are fed into other groups, the drugs are continuously fed for 7 days, after the administration for 1 hour on the 7 th day, 0.05 mL/mouse is injected into the abdominal cavity, the times of writhing of the mice in each group within 30min after the abdominal cavity injection of oxytocin are recorded, and the writhing reaction inhibition rate and the writhing incidence rate are calculated according to the following formulas. The inventors analyzed the results of treating primary dysmenorrhea in mice, and see table 1.
The torsion incidence rate is equal to the total number of torsion generating animals in each group/experimental animals in each group multiplied by 100 percent
The twisting inhibition rate is [ (twisting reaction times of model group-twisting reaction times of administration group) ÷ twisting reaction times of model group ] × 100%
Table 1 therapeutic effect of probiotic composition provided by the present invention on primary dysmenorrhea of mice
Note: SPSS 16.0 is adopted to count the times of twisting, One-way ANOVA is adopted to carry out One-way variance analysis, a Duncan method is adopted to carry out multiple comparison, the result is expressed by mean value plus or minus standard deviation, and the same column in the table is marked with different lower case letters to express that the difference between groups is obvious (P < 0.05); the same lower case letters are used to indicate that the differences between groups are not significant.
2. Human body trial
In order to verify the effect of the product in the invention on treating dysmenorrhea, the inventor carries out clinical observation on 20 cases of dysmenorrhea patients, takes product 2 as an example, 10g of the product is taken each time, 2 times a day, 7 days are taken continuously in the first 5 days, and after 1 treatment course, 3 cases are cured (main symptoms disappear, no obvious discomfort exists before and after menstrual period), accounting for 15 percent; effective (the main symptoms are obviously relieved, and the discomfort before and after the menstrual period is slight) 12 cases, accounting for 60 percent; the total effective rate is 75%.
Application of the second part of medicine-food homologous traditional Chinese medicine with menstruation regulating function
Example 4 medicinal and edible Chinese medicinal formula with menstruation regulating function
The formula A is as follows: 50g of honey-fried licorice root, 60g of medlar, 60g of red date, 30g of dried orange peel, 30g of dried ginger and 90g of longan.
And the formula B is as follows: prepared licorice root 100g, matrimony vine 120g, red jujube 200g, dried orange peel 100g, dried ginger 100g, longan 150 g.
And a formula C: 80g of honey-fried licorice root, 60g of medlar, 200g of red date, 100g of dried orange peel, 30g of dried ginger and 100g of longan.
And (3) formula D: 60g of honey-fried licorice root, 100g of medlar, 150g of red date, 60g of dried orange peel, 30g of dried ginger and 120g of longan.
And a formula E: 60g of honey-fried licorice root, 120g of medlar, 100g of red date, 60g of dried orange peel, 60g of dried ginger and 120g of longan.
Respectively taking medicinal and edible traditional Chinese medicines according to the formula, adding water (mass-volume ratio) which is 8 times of the total weight of the medicines, soaking for 2h, boiling with strong fire, decocting with slow fire for 30min, filtering, and keeping filtrate I; adding 6 times of water into the residue, boiling with strong fire, decocting with slow fire for 20min, filtering, and retaining filtrate II; mixing the first and second filtrates, vacuum concentrating under reduced pressure, and vacuum freeze drying to obtain Chinese medicinal extract product A, product B, product C, product D, and product E.
Example 5 efficacy verification of medicinal and edible traditional Chinese medicine with menstruation regulating function
The specific steps are the same as those in the embodiment 3, and the differences are that: the medicine is divided into a blank control group, a model group, a positive group, a product A group, a product B group, a product C group, a product D group and a product E group, and each traditional Chinese medicine group is provided with equal amount of traditional Chinese medicine dry matters (calculated according to 20g crude drugs/day, the daily administration dosage of mice is converted according to the body surface area, and the administration volume is 0.5 mL/mouse). The inventors analyzed the results of treating primary dysmenorrhea in mice, as shown in Table 2.
Table 2 therapeutic effect of the extract of Chinese medicinal herbs having homology of medicine and food for primary dysmenorrhea of mouse provided by the present invention
Note: SPSS 16.0 is adopted to count the times of twisting, One-way ANOVA is adopted to carry out One-way variance analysis, a Duncan method is adopted to carry out multiple comparison, the result is expressed by mean value plus or minus standard deviation, and the same column in the table is marked with different lower case letters to express that the difference between groups is obvious (P < 0.05); the same lower case letters are used to indicate that the differences between groups are not significant.
The third part has synergistic effect of medicinal and edible Chinese medicinal materials with menstruation regulating effect and probiotic bacteria
Example 6
The specific steps are the same as those in the embodiment 3, and the differences are that: the groups were divided into blank control, model, positive, product C, product 2+ product C, the dose of product 2 was the same as example 3 and the dose of product C was the same as example 5. The inventors analyzed the results of treating primary dysmenorrhea in mice, and they found in Table 3.
Table 3 therapeutic effect of the herbal and edible extract on primary dysmenorrhea of mice provided by the invention
Note: SPSS 16.0 is adopted to count the times of twisting, One-way ANOVA is adopted to carry out One-way variance analysis, a Duncan method is adopted to carry out multiple comparison, the result is expressed by mean value plus or minus standard deviation, and the same column in the table is marked with different lower case letters to express that the difference between groups is obvious (P < 0.05); the same lower case letters are used to indicate that the differences between groups are not significant.
Example 7
In order to verify the synergistic effect of the medicinal and edible traditional Chinese medicine with the function of regulating menstruation and probiotics, taking the product 2 and the product C as an example to observe the effect of treating dysmenorrhea, the inventor carries out clinical observation on 30 cases of dysmenorrhea patients, and the content of the medicine is 10g (containing 10g of crude drugs, lactobacillus rhamnosus and lactobacillus plantarum is 2.5 multiplied by 10) for each time7CFU/g, content of Bifidobacterium longum is 5 × 107CFU/g, the auxiliary material is skimmed milk powder), 2 times a day, and 7 days after the first 5 days, after 1 treatment course, 7 cases (main symptoms disappear, no obvious discomfort exists before and after menstrual period) are cured, accounting for 23.33%; 17 effective cases (the main symptoms are obviously relieved, and the discomfort before and after the menstrual period is slight) account for 56.67 percent; the total effective rate is 80%.
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.
Claims (6)
1. A probiotic composition with menstruation regulating function is characterized by consisting of lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum; in the probiotic composition, the content of the lactobacillus rhamnosus is 2.5 multiplied by 106-2.5×109CFU/g, the content of the lactobacillus plantarum is 2.5 multiplied by 106-2.5×109CFU/g, the content of Bifidobacterium longum is 5 × 106-5×109CFU/g; the rhamnose milkThe ratio of viable count of bacillus, lactobacillus plantarum and bifidobacterium longum is 1: 1: 2.
2. the probiotic composition according to claim 1, characterized in that the content of Lactobacillus rhamnosus, Lactobacillus plantarum is 2.5 x 107CFU/g, the content of Bifidobacterium longum is 5 × 107CFU/g。
3. Use of a probiotic composition according to any one of claims 1-2 for the preparation of a product for the treatment of dysmenorrhea and regulating menstruation.
4. The composition with the function of regulating menstruation is characterized by being prepared by synergistically combining probiotics and medicinal and edible traditional Chinese medicines with the function of regulating menstruation; the probiotics comprise lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium longum; the content of Lactobacillus rhamnosus is 2.5 × 106-2.5×109CFU/g, the content of the lactobacillus plantarum is 2.5 multiplied by 106-2.5×109CFU/g, the content of Bifidobacterium longum is 5 × 106-5×109CFU/g; the ratio of the number of viable bacteria of the lactobacillus rhamnosus, the lactobacillus plantarum and the bifidobacterium longum is 1: 1: 2; the medicine-food homologous traditional Chinese medicine is composed of honey-fried licorice root, medlar, red dates, dried orange peel, dried ginger and longan.
5. The composition with the function of regulating menstruation according to claim 4, wherein the medicine-food homologous traditional Chinese medicine consists of the following components in parts by weight: 5-10 parts of honey-fried licorice root, 6-12 parts of medlar, 6-20 parts of red date, 3-10 parts of dried orange peel, 3-10 parts of dried ginger and 9-15 parts of longan.
6. Use of the composition for regulating menstruation according to any one of claims 4 or 5 for the preparation of a product for treating dysmenorrhea and regulating menstruation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610846342.4A CN106309506B (en) | 2016-09-23 | 2016-09-23 | Probiotics composition with menstruation regulating function and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610846342.4A CN106309506B (en) | 2016-09-23 | 2016-09-23 | Probiotics composition with menstruation regulating function and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106309506A CN106309506A (en) | 2017-01-11 |
| CN106309506B true CN106309506B (en) | 2019-12-24 |
Family
ID=57819814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610846342.4A Active CN106309506B (en) | 2016-09-23 | 2016-09-23 | Probiotics composition with menstruation regulating function and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309506B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106962900A (en) * | 2017-04-12 | 2017-07-21 | 山东菌芝堂生物科技发展有限公司 | A kind of instant porridge for recovering menstrual period uncomfortable Intestinal Mucosal Injury in Patients Undergoing colony balance and preparation method thereof |
| KR102107443B1 (en) * | 2018-08-31 | 2020-05-07 | (주)바이오리듬 | Lactobacillus probiotics preparation for preventing or relieving the female menopausal symptoms |
| CN112138126A (en) * | 2020-08-31 | 2020-12-29 | 广州泽力医药科技有限公司 | Composition for effectively relieving dysmenorrhea and preparation method thereof |
| CN115671206B (en) * | 2022-11-17 | 2023-07-25 | 北京中科生物科技有限公司 | Traditional Chinese medicine peptide oral liquid for relieving fatigue and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103637213A (en) * | 2013-11-01 | 2014-03-19 | 胡安然 | Special meal for patients with gynopathy |
| CN103725573A (en) * | 2014-01-13 | 2014-04-16 | 江苏海昇药业有限公司 | Longan and cinnamon wine and preparation method thereof |
| CN103829250A (en) * | 2014-03-19 | 2014-06-04 | 苏州科大微龙信息技术有限公司 | Enzyme for conditioning irregular menstruation and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL215224A0 (en) * | 2011-09-18 | 2012-02-29 | Katz Daniel Dr | Vaginal danazol combined with non steroidal anti inflammatory drugs (nsaids) compositions |
-
2016
- 2016-09-23 CN CN201610846342.4A patent/CN106309506B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103637213A (en) * | 2013-11-01 | 2014-03-19 | 胡安然 | Special meal for patients with gynopathy |
| CN103725573A (en) * | 2014-01-13 | 2014-04-16 | 江苏海昇药业有限公司 | Longan and cinnamon wine and preparation method thereof |
| CN103829250A (en) * | 2014-03-19 | 2014-06-04 | 苏州科大微龙信息技术有限公司 | Enzyme for conditioning irregular menstruation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106309506A (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108671135B (en) | Traditional Chinese medicine probiotic compound for conditioning insomnia and depression | |
| KR101040721B1 (en) | Composition for alleviation of alcohol-induced hangover comprising Hovenia dulcis Thunberg contained Ssangwhatang | |
| CN106420847B (en) | Composition for assisting in protecting gastric mucosa and/or relieving gastrectasia and microecological preparation thereof | |
| CN106309506B (en) | Probiotics composition with menstruation regulating function and application thereof | |
| CN117487683A (en) | Probiotic composition with effects of resisting claustration, protecting stomach, promoting digestion and removing food retention and application thereof | |
| CN101953985A (en) | Drug with function of removing heat from lung to relieve cough | |
| CN112569323A (en) | Composition for dispelling effects of alcohol and protecting liver and application thereof | |
| CN107854495B (en) | Application of bacillus coagulans in preparation of preparation for reducing hematuria | |
| CN115838676A (en) | Traditional Chinese medicine fermentation by using novel lactobacillus plantarum strain and application | |
| CN108936628A (en) | A kind of specific full nutritional formulas and preparation method thereof that patients with cerebral apoplexy is edible | |
| KR100918629B1 (en) | Composition for prevention or treatment of liver toxicity comprising lactic acid bacteria fermented Ssangwhatang | |
| KR100918628B1 (en) | Composition for prevention or treatment of liver toxicity comprising fungus-fermented Ssangwhatang | |
| KR100988923B1 (en) | Composition for alleviation of alcohol-induced hangover comprising lactic acid bacteria fermented Ssangwhatang | |
| CN102246956A (en) | Healthcare food containing pollen pini and preparation method thereof | |
| WO2013159730A1 (en) | Food for nutritional therapy of aids | |
| US10953062B2 (en) | Anticancer pharmaceutical composition and application thereof | |
| CN109700830A (en) | A kind for the treatment of gastritis and the drug of peptic ulcer in good taste and preparation method thereof | |
| CN105749099B (en) | A kind of probiotics fermention Chinese medicine composition and its preparation method and application for treating gastric cancer | |
| CN113967243B (en) | Fermented traditional Chinese medicine preparation for preventing and treating diarrhea of poultry and preparation method thereof | |
| CN104940375A (en) | Production method for lactic acid bacteria fermented poplar flower oral liquid | |
| CN112043730A (en) | Traditional Chinese medicine biological preparation for preventing and treating animal epidemic diseases | |
| CN111991521A (en) | Tea buccal tablet for reducing high blood pressure, high blood sugar and high blood lipid and preparation method thereof | |
| CN110404006A (en) | A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis | |
| KR20190049162A (en) | Functional fermented composition for anti-obesity, manufacturing method thereof, and food comprsing the same | |
| CN107375392A (en) | One kind treats tetanic Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180802 Address after: 271000 Laboratory Building of Shandong Baolai Lilai Bioengineering Co., Ltd. south of Pioneering Street, Eastern New District, Taishan District, Tai'an City, Shandong Province Applicant after: Tai'an Da Fan Shennong biological Co., Ltd. Address before: 271600 Jinniu Mountain street, Feicheng, Shandong 001 Applicant before: Taian Dafan Shennong Pharmaceutical Co.,Ltd. |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20181218 Address after: 271600 Jinniu Mountain street, Feicheng, Tai'an, Shandong 001 Applicant after: Taian Dafan Shennong Pharmaceutical Co.,Ltd. Address before: 271000 Laboratory Building of Shandong Baolai Lilai Bioengineering Co., Ltd. south of Pioneering Street, Eastern New District, Taishan District, Tai'an City, Shandong Province Applicant before: Tai'an Da Fan Shennong biological Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200427 Address after: 271021 Experimental Building of Shandong Baolailailailailailai Bioengineering Co., Ltd. to the South of Pioneering Street, East New District, Taishan District, Taian City, Shandong Province Patentee after: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. Address before: 271600 No. 001 Jinniu Road, Feicheng, Shandong, Tai'an Patentee before: TAIAN DAFANSHENNONG PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 271000 first floor, No. 17, Huayuan Road, Shanggao street, Taishan District, Tai'an City, Shandong Province Patentee after: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. Address before: 271021 Experimental Building of Shandong Baolailailailailailai Bioengineering Co., Ltd. to the South of Pioneering Street, East New District, Taishan District, Taian City, Shandong Province Patentee before: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. |